ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  Detection of mutations in the enhancer 2/core promoter region of hepatitis B virus in patients with chronic hepatitis B virus infection: comparison with mutations in precore and core regions in relation to clinical status.
 PMID: 10089043       1999       Journal of medical virology
Abstract: The most frequent substitutions from A to T at nucleotide 1764 and from G to A at nucleotide 1766 were seen in none of the 10 asymptomatic carriers and in 14 (70%) of the 20 chronic liver disease patients.


  Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus.
 PMID: 10091998       1999       The Journal of general virology
Abstract: The L515M and M539V mutations provided only partial resistance while the M539I mutation conferred a high degree of lamivudine resistance.
Abstract: The M539I mutation reduced replication competence.
Abstract: The M539I substitution in the conserved YMDD motif occurs independently of other changes, whereas the M539V substitution is associated with an additional upstream change (L515M).
Abstract: The combination of the L515M and M539V mutations gave an intermediate level of replication competence, compared with either mutation alone, and increased resistance to lamivudine.


  Detection of hepatitis B surface antigen mutants and their integration in human hepatocellular carcinoma.
 PMID: 10211946       1999       Cancer letters
Abstract: Southern blot analysis indicated that the HBsAg mutant with the Glycine to Arginine change at position 145 was integrated in HCC, whereas those with a Threonine at position 133 instead of a Methionine were identified in the serum of aggressive HCC.


  Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir.
 PMID: 10320044       1999       Antiviral research
Abstract: Both the wild type HBV and lamivudine-related mutants with the Gly145-->Arg145 HBsAg mutation were suppressed following ganciclovir treatment, indicating a beneficial additive effect of both drugs against different forms of HBV mutants.
Abstract: Here we report the identification of a novel type of lamivudine-related mutations located in both the polymerase (YM552DD-->Y1552DD) and the 'a' epitope of HBsAg (Gly130-->Asp130).
Abstract: The same virus carried a HBsAg Gly145-->Arg145 mutation prior to therapy.


  Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues.
 PMID: 10353255       1999       Biochemical pharmacology
Abstract: It was found that the L526M mutation alone caused greater resistance to penciclovir (PCV) than did the V553I mutation alone.
Abstract: The A546V mutation had no impact on the sensitivity to L(-)SddC, L-FMAU, and PCV.
Abstract: When these single mutations were coupled with the M550V/I mutation, all the double mutants were resistant to those drugs.


  The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen.
 PMID: 10364324       1999       Journal of virology
Abstract: We have dissected further the relationship between the intracellular and extracellular phenotypes of mutant F97L.


  Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.
 PMID: 10377169       1999       The Journal of clinical investigation
Abstract: In this study, susceptibility of wild-type and lamivudine-resistant HBV M552I, M552V, and L528M/M552V mutants to other reverse transcriptase inhibitors was investigated by transient transfection of full-length HBV DNA into human hepatoma cells.


  Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.
 PMID: 10385663       1999       Hepatology (Baltimore, Md.)
Abstract: However, 7 patients developed a breakthrough within 12, 29 (n = 2), 32, 37, 54, and 145 weeks under treatment with LAM associated with the methionine-to-valine signature mutation (M552V) in the YMDD motif in all.
Abstract: Our results indicate that the L528M mutation is a risk factor for LAM breakthrough, because breakthrough during LAM occurred earlier in patients with this mutation (50 +/- 10 weeks vs.
Abstract: With FCV, no unique, but a dominant, resistance pattern with the L528M mutation was identified for patients with breakthrough under FCV.


  Perspectives for the treatment of hepatitis B virus infections.
 PMID: 10418752       1999       International journal of antimicrobial agents
Abstract: L528M and M552V/I) in the HBV DNA polymerase upon long-term treatment.


  Liver graft infection by HBV S-gene mutants in transplant patients receiving long-term HBIg prophylaxis.
 PMID: 10430358       1999       Hepato-gastroenterology
Abstract: A HBV S-gene mutant containing a G to A nucleotide mutation at position 587, converting Glycine to Arginine (G145A), was identified in all three patients as the dominant population at reinfection but not pre-transplantation.
Abstract: CONCLUSIONS: These data demonstrate that long-term polyclonal anti-HBs immunoprophylaxis selected the most commonly described G145R S-gene escape HBV variant which became the dominant virus population and was responsible for graft infection.
Abstract: Therefore, immunoglobulins with high affinity for the G145R HBs variant should be included in HBIg to prevent recurrent HBV infection in transplant patients.



Browser Board

 Co-occurred Entities




   Filtrator